DUBINE Cream Ref.[7698] Active ingredients: Ozenoxacin

Source: Health Products Regulatory Authority (IE)  Revision Year: 2018  Publisher: Ferrer Internacional, S.A., Gran VĂ­a Carlos III, 94, 08028, Barcelona, Spain

Product name and form

Dubine 10 mg/g cream.

Pharmaceutical Form

Cream.

Pale yellow, homogeneous cream.

Qualitative and quantitative composition

Each gram of cream contains 10 mg of ozenoxacin.

Excipient(s) with known effect: Each gram of cream contains 1mg of benzoic acid (E-210), 150 mg of propylene glycol and 40 mg of stearyl alcohol.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Ozenoxacin

Ozenoxacin is a non-fluorinated quinolone with a dual inhibitory activity against bacterial DNA replication enzymes, DNA gyrase A and topoisomerase IV. Ozenoxacin is characterized by its potency and bactericidal activity against clinical bacterial isolates involved in skin infections, including S. aureus and S. pyogenes.

List of Excipients

Macrogol stearate
Ethylene glycol monopalmitostearate
Oleoyl macrogol glycerides
Octyldodecanol
Stearyl alcohol
Propylene glycol
Benzoic acid (E210)
Purified water

Pack sizes and marketing

Aluminium tube with a white screw cap. The tube has an epoxy-phenolic internal lacquer and a sealant lacquer at the tube end.

Dubine is available in tubes containing 10 g of cream.

Marketing authorization holder

Ferrer Internacional, S.A., Gran VĂ­a Carlos III, 94, 08028, Barcelona, Spain

Marketing authorization dates and numbers

PA1744/003/001

Date of first authorisation: 16th June 2017

Drugs

Drug Countries
DUBINE Poland

Š All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.